Amino Acid-Based Metabolic Indexes Identify Patients With Chronic Obstructive Pulmonary Disease And Further Discriminates Patients In Advanced BODE Stages

References

• López‐Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. doi:10.1111/resp.1266026494423
   PubMed Web of Science ®Google Scholar
• Mirza S, Clay RD, Koslow MA, Scanlon PD COPD guidelines: a review of the 2018 GOLD report. Paper presented at: Mayo Clinic Proceedings 2018.
   Google Scholar
• Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa02132214999112
   PubMed Web of Science ®Google Scholar
• Ong K-C, Earnest A, Lu S-J. A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. Chest. 2005;128(6):3810–3816. doi:10.1378/chest.128.6.381016354849
   PubMed Web of Science ®Google Scholar
• Marin JM, Carrizo SJ, Casanova C, et al. Prediction of risk of COPD exacerbations by the BODE index. Respir Med. 2009;103(3):373–378. doi:10.1016/j.rmed.2008.10.00419013781
   PubMed Web of Science ®Google Scholar
• Jones P, Agusti A. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(4):822–832. doi:10.1183/09031936.06.0014510416585091
   PubMed Web of Science ®Google Scholar
• Beger RD, Dunn W, Schmidt MA, et al. Metabolomics enables precision medicine:“a white paper, community perspective”. Metabolomics. 2016;12(9):149. doi:10.1007/s11306-016-1094-627642271
   PubMed Web of Science ®Google Scholar
• Ubhi BK, Riley JH, Shaw PA, et al. Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur Respir J. 2012;40(2):345–355. doi:10.1183/09031936.0011241122183483
   PubMed Web of Science ®Google Scholar
• Ubhi BK, Cheng KK, Dong J, et al. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst. 2012;8(12):3125–3133. doi:10.1039/c2mb25194a23051772
   PubMed Web of Science ®Google Scholar
• Chen Q, Deeb RS, Ma Y, Staudt MR, Crystal RG, Gross SS. Serum metabolite biomarkers discriminate healthy smokers from COPD smokers. PLoS One. 2015;10(12):e0143937.26674646
   PubMed Web of Science ®Google Scholar
• Bregy L, Nussbaumer-Ochsner Y, Sinues PM-L, et al. Real-time mass spectrometric identification of metabolites characteristic of chronic obstructive pulmonary disease in exhaled breath. Clin Mass Spectrom. 2018;7:29–35.
   Google Scholar
• Wang C-H, Cheng M-L, Liu M-H. Simplified plasma essential amino acid-based profiling provides metabolic information and prognostic value additive to traditional risk factors in heart failure. Amino Acids. 2018;50(12):1739–1748.30203393
   PubMed Web of Science ®Google Scholar
• Snowden S, Dahlén S-E, Wheelock CE. Application of metabolomics approaches to the study of respiratory diseases. Bioanalysis. 2012;4(18):2265–2290. doi:10.4155/bio.12.21823046268
   PubMed Web of Science ®Google Scholar
• Cheng M-L, Wang C-H, Shiao M-S, et al. Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. J Am Coll Cardiol. 2015;65(15):1509–1520. doi:10.1016/j.jacc.2015.02.01825881932
   PubMed Web of Science ®Google Scholar
• Wang C-H, Cheng M-L, Liu M-H. Amino acid-based metabolic panel provides robust prognostic value additive to b-natriuretic peptide and traditional risk factors in heart failure. Dis Markers. 2018;2018.
   Web of Science ®Google Scholar
• de Miguel Díez J, Morgan JC, García RJ. The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis. 2013;8:305. doi:10.2147/COPD.S3123623847414
   PubMed Web of Science ®Google Scholar
• Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol. 2002;85(1):51–66. doi:10.1016/s0167-5273(02)00233-412163209
   PubMed Web of Science ®Google Scholar
• Dempsey TM, Scanlon PD Pulmonary function tests for the generalist: a brief review. Paper presented at: Mayo Clinic Proceedings 2018.
   Google Scholar
• Bestall J, Paul E, Garrod R, Garnham R, Jones P, Wedzicha J. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586. doi:10.1136/thx.54.7.58110377201
   PubMed Web of Science ®Google Scholar
• Jones P, Harding G, Berry P, Wiklund I, Chen W, Leidy NK. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.0010250919720809
   PubMed Web of Science ®Google Scholar
• Laboratories ACoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–117. doi:10.1164/ajrccm.166.1.at110212091180
   PubMed Web of Science ®Google Scholar
• Rantanen T, Masaki K, Foley D, Izmirlian G, White L, Guralnik J. Grip strength changes over 27 yr in Japanese-American men. J Appl Physiol. 1998;85(6):2047–2053. doi:10.1152/jappl.1998.85.6.20479843525
   PubMed Web of Science ®Google Scholar
• Gea J, Agustí A, Roca J. Pathophysiology of muscle dysfunction in COPD. J Appl Physiol. 2013;114(9):1222–1234. doi:10.1152/japplphysiol.00981.201223519228
   PubMed Web of Science ®Google Scholar
• Remels A, Gosker HR, Langen RC, Schols AM. The mechanisms of cachexia underlying muscle dysfunction in COPD. J Appl Physiol. 2012;114(9):1253–1262. doi:10.1152/japplphysiol.00790.201223019314
   PubMed Web of Science ®Google Scholar
• Pesci A, Balbi B, Majori M, et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J. 1998;12(2):380–386. doi:10.1183/09031936.98.120203809727789
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–2653. doi:10.1056/NEJMoa03215815215480
   PubMed Web of Science ®Google Scholar
• Ansarin K, Chatkin J, Ferreira I, Gutierrez C, Zamel N, Chapman K. Exhaled nitric oxide in chronic obstructive pulmonary disease: relationship to pulmonary function. Eur Respir J. 2001;17(5):934–938. doi:10.1183/09031936.01.1750934011488329
   PubMed Web of Science ®Google Scholar
• Brindicci C, Ito K, Resta O, Pride N, Barnes P, Kharitonov S. Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J. 2005;26(1):52–59. doi:10.1183/09031936.04.0012530415994389
   PubMed Web of Science ®Google Scholar
• Lu Z, Huang W, Wang L, Xu N, Ding Q, Cao C. Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:2695–2705. doi:10.2147/COPD.S16578030214187
   PubMed Web of Science ®Google Scholar
• Hu J, Mahmoud MI, El-Fakahany EE. Polyamines inhibit nitric oxide synthase in rat cerebellum. Neurosci Lett. 1994;175(1–2):41–45. doi:10.1016/0304-3940(94)91073-17526294
   PubMed Web of Science ®Google Scholar
• Bauer PM, Fukuto JM, Buga GM, Pegg AE, Ignarro LJ. Nitric oxide inhibits ornithine decarboxylase by S-nitrosylation. Biochem Biophys Res Commun. 1999;262(2):355–358. doi:10.1006/bbrc.1999.121010462479
   PubMed Web of Science ®Google Scholar
• J-M T, Henno P, Leroy I, et al. Role of the nitric oxide synthase/arginase balance on bronchial reactivity in patients with chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2008;294:L489–L497.17675371
   PubMed Web of Science ®Google Scholar
• Maarsingh H, Pera T, Meurs H. Arginase and pulmonary diseases. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(2):171. doi:10.1007/s00210-008-0286-718437360
   PubMed Web of Science ®Google Scholar
• Pera T, Zuidhof A, Smit M, et al. Arginase inhibition prevents inflammation and remodeling in a guinea pig model of chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2014;349(2):229–238. doi:10.1124/jpet.113.21013824563530
   PubMed Web of Science ®Google Scholar
• Murray AJ, Montgomery HE. How wasting is saving: weight loss at altitude might result from an evolutionary adaptation. Bioessays. 2014;36(8):721–729. doi:10.1002/bies.20140004224917038
   PubMed Web of Science ®Google Scholar
• Vendelbo MH, Møller AB, Christensen B, et al. Fasting increases human skeletal muscle net phenylalanine release and this is associated with decreased mTOR signaling. PLoS One. 2014;9(7):e102031.25020061
   PubMed Web of Science ®Google Scholar
• Neurauter G, Schrocksnadel K, Scholl-Burgi S, et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab. 2008;9(7):622–627.18781914
   PubMed Web of Science ®Google Scholar
• Pitkänen H, Oja S, Kemppainen K, Seppä J, Mero A. Serum amino acid concentrations in aging men and women. Amino Acids. 2003;24(4):413–421. doi:10.1007/s00726-002-0338-012768504
   PubMed Web of Science ®Google Scholar